Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

D. M. Fraser; F. M. Sullivan; A. M. Thompson; C. McCowan

doi:10.1038/bjc.2014.264

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

D. M. Fraser, F. M. Sullivan, A. M. Thompson, C. McCowan (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

96 Citations (Scopus)

258 Downloads (Pure)

Abstract

Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models. The main outcome measures were all-cause mortality and breast cancer-specific mortality.Results:Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31 December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52-74). One thousand eight hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%) patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR=0.53, 95% CI=0.45-0.63, P

Original language	English
Pages (from-to)	623-627
Number of pages	5
Journal	British Journal of Cancer
Volume	111
Issue number	3
Early online date	19 Jun 2014
DOIs	https://doi.org/10.1038/bjc.2014.264
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2014.264

Publisher final version
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Final published version, 131 KBLicence: CC BY-NC-SA

Cite this

@article{3749bd2e496241f09bab0c058d584e04,

title = "Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study",

abstract = "Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models. The main outcome measures were all-cause mortality and breast cancer-specific mortality.Results:Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31 December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52-74). One thousand eight hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%) patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR=0.53, 95% CI=0.45-0.63, P",

author = "Fraser, {D. M.} and Sullivan, {F. M.} and Thompson, {A. M.} and C. McCowan",

year = "2014",

doi = "10.1038/bjc.2014.264",

language = "English",

volume = "111",

pages = "623--627",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Aspirin use and survival after the diagnosis of breast cancer

T2 - a population-based cohort study

AU - Fraser, D. M.

AU - Sullivan, F. M.

AU - Thompson, A. M.

AU - McCowan, C.

PY - 2014

Y1 - 2014

N2 - Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models. The main outcome measures were all-cause mortality and breast cancer-specific mortality.Results:Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31 December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52-74). One thousand eight hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%) patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR=0.53, 95% CI=0.45-0.63, P

AB - Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models. The main outcome measures were all-cause mortality and breast cancer-specific mortality.Results:Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31 December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52-74). One thousand eight hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%) patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR=0.53, 95% CI=0.45-0.63, P

UR - http://www.scopus.com/inward/record.url?scp=84905225509&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.264

DO - 10.1038/bjc.2014.264

M3 - Article

C2 - 24945997

SN - 0007-0920

VL - 111

SP - 623

EP - 627

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

The Scottish eHealth Informatics Research Centre (E-HIRCs) (Joint with Universities of Aberdeen, Glasgow, Edinburgh, Strathclyde, St Andrews & Leicester and ISD)

Cite this

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

The Scottish eHealth Informatics Research Centre (E-HIRCs) (Joint with Universities of Aberdeen, Glasgow, Edinburgh, Strathclyde, St Andrews & Leicester and ISD)

Cite this